

# Ifinatamab Biosimilar, Human B7-H3 Monoclonal Antibody

Catalog No.: YR0156

## Basic Information

### Molecular Weight

150 kDa

### Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

### Sterility

0.2 μm filtration

### Aggregation

<5% Determined by SECP

### Purity

>95% Determined by SDS-PAGE

## Background

What is ifinatamab biosimilar research grade? Ifinatamab is a humanized IgG1-kappa monoclonal antibody against the human B7-H3 (CD276) protein, a type I transmembrane protein belonging to the B7 family which includes immune checkpoint molecules CTLA-4 and PD-L1. B7-H3 is highly expressed in various types of solid tumors with low expression in normal (healthy) tissues. It was reported that B7-H3 overexpression is associated with poor prognosis in several types of cancers. Ifinatamab biosimilar uses the same protein sequences as the therapeutic antibody ifinatamab.

## Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

## Immunogen Information

### Clone

Ifinatamab

### Isotype

Human IgG1 kappa

### Immunogen

Human B7-H3

### Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

### Recommended Dilution Buffer

1×PBS pH 7.0

## Contact

☎ | 400-999-6126

✉ | [cn.market@abclonal.com.cn](mailto:cn.market@abclonal.com.cn)

🌐 | [www.abclonal.com.cn](http://www.abclonal.com.cn)

## Product Information

### Production

Purified from cell culture supernatant in an animal-free facility

### Purification

Protein A or G purification

### Storage

2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)